+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells



BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells



Cancer Research 70(21): 8782-8791



Evasion of apoptosis plays a key role in cancer development, drug resistance, and recurrence. The BRCA1 locus product protein BRCA1-IRIS is overexpressed in several cisplatin-resistant ovarian cancer cell lines, but its relationship to resistance is uncertain. Here, we show that in human ovarian surface epithelial (HOSE) cells, overexpression of BRCA1-IRIS triggers expression of the antiapoptotic protein survivin. Negative modulation of phosphatidylinositol 3-kinase (PI3K) signaling or AKT silencing reduced survivin expression in this setting. Conversely, silencing BRCA1-IRIS in ovarian cancer cell lines derepressed PTEN expression along with the antiapoptotic AKT targets FOXO1 and FOXO3a, suppressing survivin expression. Cisplatin (≤50 μmol/L) exposure was sufficient to activate expression of the BRCA1-IRIS-AKT-survivin cascade in HOSE cells, whereas under similar conditions cisplatin failed to induce apoptosis in ovarian cancer cell lines expressing this regulatory cascade. Mechanistic investigations indicated that BRCA1-IRIS triggers survivin expression through a PI3K/AKT-dependent pathway involving NF-κB, but also through a PI3K/AKT-independent pathway involving PTEN, FOXO1, and FOXO3a. Our findings indicate how BRCA1-IRIS overexpression prevents chemotherapy-induced cell death by upregulating expression of survivin, and they highlight this regulatory cascade as a candidate focus to improve treatment of advanced drug-resistant ovarian cancers.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051744477

Download citation: RISBibTeXText

PMID: 20940403

DOI: 10.1158/0008-5472.CAN-10-1352


Related references

Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. International Journal of Clinical and Experimental Medicine 8(11): 20565-20572, 2016

BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells. Oncotarget 3(3): 299-313, 2012

HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells. Journal of Ovarian Research 9(1): 28, 2017

BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Oncotarget 8(6): 10114-10135, 2017

Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biology & Therapy 10(8): 788-795, 2010

Overexpression of thioredoxin does not confer cisplatin resistance in transfected human ovarian and colon cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 318-319, 1996

Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biology and Therapy 10(8): 788-795, 2011

Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 44: 809, 2003

BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells. Biomarker Insights 1: 49-59, 2007

PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression. Biochemical and Biophysical Research Communications 444(2): 141-146, 2014

Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. International Journal of Cancer 122(3): 534-546, 2007

Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Medicine 4(5): 745-758, 2016

Induction of breast cancer in wild type p53 cells by BRCA1-IRIS overexpression. Hawaii Medical Journal 69(8): 200-201, 2010

The role of BRCA1-IRIS in ovarian cancer formation, drug resistance and progression. Oncoscience 3(5-6): 145-146, 2016

Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo. Cellular Physiology and Biochemistry 39(1): 242-252, 2017